Lauren Davis
Physician Assistant · Saint Louis, MONPI 1922576941
Payments from drug & device makers
Across 170 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$659
- Takeda Pharmaceuticals U.S.A., Inc.$449
- Regeneron Healthcare Solutions, Inc.$420
- CSL Behring$398
- Amgen$184
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,09596%
- Education$1504%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $1,008 |
| Sanofi | 35 | $659 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $449 |
| Regeneron Healthcare Solutions, Inc. | 12 | $420 |
| CSL Behring | 17 | $398 |
| Amgen | 9 | $184 |
| Grifols USA, LLC | 10 | $178 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $141 |
| Novartis | 2 | $141 |
| AbbVie | 3 | $121 |
| GSK | 2 | $109 |
| Organon | 1 | $107 |
| Pfizer | 3 | $61 |
| Hikma Pharmaceuticals USA | 3 | $55 |
| Kaleo, Inc. | 3 | $48 |
| Octapharma USA, Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $35 |
| Pharming Healthcare, Inc. | 1 | $29 |
| Blueprint Medicines Corporation | 1 | $24 |
| Biocryst US Sales Co., LLC | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,245 in reported general payments places this provider in the 90th percentile of 1,380 physician assistant providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $13,288 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,685 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,678 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $678 |
| Azelastine Hcl | 21 | $519 |
| Fluticasone Propionate | 17 | $471 |
| Ipratropium Bromide | 15 | $445 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $270 |
| Prednisone | 13 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $109 | $17,96631 claims |
| AstraZenecaSymbicort | $1,008 | $6,68515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,380 physician assistant providers in Missouri.
Other physician assistant in Saint Louis
- Kimberly BrownSaint Louis$28K
- Michael HesselSaint Louis$19K
- Erica WestbrooksSaint Louis$19K
- Christine EdwardsSaint Louis$18K
- Andrea MartinSaint Louis$17K
- Rachael HartkeSaint Louis$16K
- Kristen SchreiberSaint Louis$14K
- Jonathan PriceSaint Louis$10K
- Yongzhong WeiSaint Louis$9K
- Lisa RoelleSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.